EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy

Sofia Dallavalle iD, Gabriele Campagnoli iD, Paola Pastena, Alessandro Martinino, Davide Schiliró, Francesco Giovinazzo iD

Medicina · 2024

DOI: 10.3390/medicina60071070 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicina, 2024. Verfasst von Sofia Dallavalle und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Surgery, University of Milan, 20122 Milan, Italy. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) ranks among the 15 most prevalent cancers globally, characterized by aggressive growth and late-stage diagnosis. Advances in imaging and surgical techniques have redefined the classification of pancreatic PDAC into resectable, borderline resectable, and locally advanced pancreatic cancer. While surgery remains the most effective treatment, only 20% of patients are eligible at diagnosis, necessitating innovative strategies to improve outcomes. Therefore, traditional treatment paradigms, primarily surgical resection for eligible patients, are increasingly supplemented by neoadjuvant therapies (NAT), which include chemotherapy, radiotherapy, or a combination of both. By administering systemic therapy prior to surgery, NAT aims to reduce tumor size and increase the feasibility of complete surgical resection, thus enhancing overall survival rates and potentially allowing more patients to undergo curative surgeries. Recent advances in treatment protocols, such as FOLFIRINOX and gemcitabine-nab-paclitaxel, now integral to NAT strategies, have shown promising results in increasing the proportion of patients eligible for surgery by effectively reducing tumor size and addressing micrometastatic disease. Additionally, they offer improved response rates and survival benefits compared to traditional regimes. Despite these advancements, the role of NAT continues to evolve, necessitating ongoing research to optimize treatment regimens, minimize adverse effects, and identify patient populations that would benefit most from these approaches. Through a detailed analysis of current literature and recent clinical trials, this review highlights the transformative potential of NAT in managing PDAC, especially in patients with borderline resectable or locally advanced stages, promising a shift towards more personalized and effective management strategies for PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyPancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansAntineoplastic Combined Chemotherapy ProtocolsFluorouracilOxaliplatinPancreatectomyIrinotecanLeucovorin

Stichwörter der Autor:innen

managementneoadjuvant therapypancreatic cancerpancreatic ductal adenocarcinomaresectability

Substanzen

folfirinoxFluorouracilOxaliplatinIrinotecanLeucovorin

Autor:innen und Institutionen

  • Faculty of Medicine and Surgery, University of Milan, 20122 Milan, Italy.
  • Department of Medicine, Stony Brook Medicine, Stony Brook, NY 11794, USA.
  • Department of Surgery, Duke University, Durham, NC 27710, USA.
  • Department of Surgery, Saint Camillus Hospital, 31100 Treviso, Italy.
  • Department of Surgery, UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy.
  • Department of Surgery, Agostino Gemelli University Hospital, 00168 Rome, Italy.

ORCID-Profile: Sofia Dallavalle, Gabriele Campagnoli, Francesco Giovinazzo

Zitieren

APA

Dallavalle, S., Campagnoli, G., Pastena, P., Martinino, A., Schiliró, D., & Giovinazzo, F. (2024). New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy. Medicina. https://doi.org/10.3390/medicina60071070

Vancouver

Dallavalle S, Campagnoli G, Pastena P, Martinino A, Schiliró D, Giovinazzo F. New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy. Medicina. 2024. doi:10.3390/medicina60071070

BibTeX
@article{Dallavalle2024,
  author = {Dallavalle, Sofia and Campagnoli, Gabriele and Pastena, Paola and Martinino, Alessandro and Schiliró, Davide and Giovinazzo, Francesco},
  title = {New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy},
  journal = {Medicina},
  year = {2024},
  doi = {10.3390/medicina60071070}
}
Kostenlos starten →